HOME >> BIOLOGY >> NEWS
AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.

Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and market AVAX Technologies' autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. M-Vax is AVAX's lead cancer vaccine and is currently being evaluated in the U.S. in a multicenter pivotal registration trial for Stage III melanoma and in a Phase 2 trial for Stage IV melanoma.

Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) from AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). Under the terms of the agreement, AVAX Technologies has been granted an option to purchase common stock equivalent to 5% of AVT's fully diluted shares. AVT began trading on the Australian Stock Exchange (ASX) under the symbol "AVT" on March 10, 2000.

Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to see AVT increasing their investment in our promising joint venture in Australia. This additional capital investment represents their enthusiasm for the potential of our product and our marketing strategy. We continue to believe that the Australian market allows us to truly demonstrate the validity of our business model and our ability to effectively market individualized product."

In 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, a therapeutic cancer vacc
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext. 34
AVAX Technologies, Inc.
5-Apr-2000


Page: 1 2

Related biology news :

1. Regeneration Technologies introduces advancements at AAOS
2. Palatin Technologies PT-141 increases sexual behavior in female animals
3. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
4. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
5. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
6. AVAX Technologies AC Vaccine™ improves relapse-free survival
7. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
8. First International Congress on Telehealth and Multimedia Technologies Story Ideas
9. Technologies Track, Map Fish Behavior
10. USGS Contributions Enhance Public Health Research, Scientists Showcase Technologies At San Diego Meeting
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2019)... ... August 28, 2019 , ... Lajollacooks4u has expanded its team as it gears ... events company has seen record growth in 2019, having hosted a multitude of team-building ... Illumina, have all visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard ...
(Date:8/27/2019)... ... August 27, 2019 , ... Advancements with Ted Danson ... is scheduled to broadcast 4Q/2019. Check local listings for more information. , ... manufacturing company. The show will highlight how Debiopharm is working to champion the ...
(Date:8/21/2019)... (PRWEB) , ... August 20, 2019 , ... ... development and commercialization of bioactive technologies for the spine, today announced the 510(K) ... features a unique surface modification that is proven to improve osseointegration through superior ...
Breaking Biology News(10 mins):
(Date:8/29/2019)... ... 28, 2019 , ... DuPont Nutrition & Biosciences will offer ... the International Baking Industry Expo, September 8 to 11, in booth 5015. DuPont ... cost and waste reduction and from maintaining freshness throughout shelf life to reformulating ...
(Date:8/23/2019)... Wis. (PRWEB) , ... August 22, 2019 , ... The ... some of the most harmful germs and pathogens on hard surfaces including E. Coli, ... leaves behind no chemical residues. For more information, visit the product page at rovingblue.com ...
(Date:8/8/2019)... FRANCISCO (PRWEB) , ... August 08, 2019 , ... ... Intelligent Virtual Agents for sales and service organizations, today announced that the ... Value Leadership Award for the IVA market . Inference will officially accept the ...
(Date:8/6/2019)... ... August 06, 2019 , ... The National Science Foundation ... a community project that will engage middle and early high school students in ... Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners presenting the authentic ...
Breaking Biology Technology:
Cached News: